Table 2.
Susceptibility of the Moraxella catarrhalis isolates in Youyang, Zhongjiang and total profiles according to EUCAST, CLSI and BSAC
| Antibiotics* | Youyang | Zhongjiang | Total | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I% | R% | MIC50 | MIC90 | MIC Range | I% | R% | MIC50 | MIC90 | MIC Range | I% | R% | MIC50 | MIC90 | MIC Range | ||
| EUCASTa | AMP | – | – | 2 | 4 | 0.016~ 16 | – | – | 2 | 6 | 0.032~ 12 | – | – | 2 | 6 | 0.032–12 |
| AMC | – | 0 | 0.19 | 0.38 | 0.016~ 0.38 | – | 0 | 0.25 | 0.25 | 0.016~ 0.38 | – | 0 | 0.25 | 0.25 | 0.016–0.38 | |
| CXM | 8.9 | 0 | 2 | 4 | 0.023~ 8 | 18.2 | 1.3 | 3 | 6 | 0.047~ 16 | 12.9 | 0.6 | 3 | 6 | 0.047–16 | |
| CAZ | – | – | 0.125 | 0.38 | 0.023~ 2 | – | – | 0.094 | 0.38 | 0.032~ 1 | – | – | 0.094 | 0.38 | 0.032–1 | |
| FEP | – | 4.0 | 1.5 | 4 | 0.064~ 6 | – | 1.3 | 1.5 | 4 | 0.19~ 6 | – | 2.8 | 1.5 | 4 | 0.19–6 | |
| CIP | – | 2.0 | 0.047 | 0.19 | 0.016~ 1 | – | 5.2 | 0.047 | 0.094 | 0.016~ 1 | – | 3.4 | 0.047 | 0.094 | 0.016–1 | |
| ERY | 28.7 | 64.4 | 0.75 | > 256 | 0.047~ > 256 | 11.7 | 79.2 | 2 | > 256 | 0.19~ > 256 | 21.3 | 70.8 | 2 | 256 | 0.19- > 256 | |
| MEM | – | 0 | 0.006 | 0.008 | 0.003~ 0.38 | – | 0 | 0.006 | 0.008 | 0.003~ 0.023 | – | 0 | 0.006 | 0.008 | 0.003–0.38 | |
| TCY | 3.0 | 5.9 | 0 | 3.9 | 1.7 | 5.1 | ||||||||||
| CHL | – | 4.0 | – | 3.9 | – | 3.9 | ||||||||||
| SXT | 9.9 | 30.7 | 7.8 | 3.9 | 9.0 | 19.1 | ||||||||||
| CLSIb | AMC | – | 0 | 0.19 | 0.38 | 0.016~ 0.38 | – | 0 | 0.25 | 0.25 | 0.016~ 0.38 | – | 0 | 0.25 | 0.25 | 0.016–0.38 |
| CXM | 8.9 | 0 | 2 | 4 | 0.023~ 8 | 18.2 | 1.3 | 3 | 6 | 0.047~ 16 | 12.9 | 0.6 | 3 | 6 | 0.047–16 | |
| CAZ | -# | -# | 0.125 | 0.38 | 0.023~ 2 | -# | -# | 0.094 | 0.38 | 0.032~ 1 | -# | -# | 0.094 | 0.38 | 0.032–1 | |
| CIP | -# | -# | 0.047 | 0.19 | 0.016~ 1 | -# | -# | 0.047 | 0.094 | 0.016~ 1 | -# | -# | 0.047 | 0.094 | 0.016–1 | |
| ERY | 48.5 | 15.8 | 0.75 | > 256 | 0.047~ > 256 | 44.1 | 35.1 | 2 | > 256 | 0.19~ > 256 | 47.8 | 23.0 | 2 | > 256 | 0.19- > 256 | |
| TCY | 20.8 | 5.9 | 3.9 | 3.9 | 13.5 | 5.1 | ||||||||||
| SXT | 6.9 | 16.8 | 0 | 1.3 | 3.9 | 10.1 | ||||||||||
| BSACc | AMP | – | 68.3 | 2 | 4 | 0.016~ 16 | – | 81.8 | 2 | 6 | 0.032~ 12 | – | 74.2 | 2 | 6 | 0.032–12 |
| CXM | 45.5 | 49.5 | 2 | 4 | 0.023~ 8 | 44.2 | 53.2 | 3 | 6 | 0.047~ 16 | 44.9 | 51.1 | 3 | 6 | 0.047–16 | |
| TCY | – | 5.9 | – | 3.9 | – | 5.1 | ||||||||||
| SXT | – | 19.8 | – | 1.3 | – | 11.8 | ||||||||||
aEUCAST European Committee on Antimicrobial Susceptibility Testing, bCLSI Clinical and Laboratory Standards Institute, cBSAC British Society for Antimicrobial Chemotherapy, *AMP ampicillin, AMC amoxicillin–clavulanic acid, CXM cefuroxime, CAZ ceftazidime, FEP cefepime, CIP ciprofloxacin, ERY eryciprofloxacin, MEM meropenem, TCY tetracycline, CHL chloramphenicol, SXT sulfamethoxazole–trimethoprim, # no breakpoints were listed in the according criterion, but the other “-“s mean no data